Hospital Leaders Can Follow the Breast Cancer Pill Home
The hormone pill starts after she leaves. Hospital leaders can set a home plan, include the caregiver, and see trouble before the next visit.

Key takeaways
- The hormone pill is taken at home for years, not in the hospital.
- In a large U.S. claims study, 48.1% of patients were not adherent to oral cancer medicine.
- Stopping early, and missing doses, were both linked with a higher chance of death.
- A shared home plan, a named caregiver, and alerts only at a set threshold can close the handoff.
- Ask for a demo if your discharge plan ends when the packet is signed.
The discharge packet is signed. The ride home is short. Then the hormone pill starts, and it may go on for five years or more. That pill is not taken on the unit. It is taken at the kitchen table, long after the bed is free.
For many women with hormone receptor-positive breast cancer, the medicine after surgery or after the visit is a daily pill. It may be tamoxifen or an aromatase inhibitor. The hospital owns the handoff. The years of the pill happen at home.
The risk shows up after she leaves
Oral cancer medicine is easy to miss once the visit is over. Vyas and colleagues studied U.S. claims from 2010 to 2018. They found that 48.1% of patients were not adherent to oral anticancer medicine (Journal of Managed Care and Specialty Pharmacy, 2022). The homepage figure of 48% within six months of starting oral treatment points to that same gap.
Breast cancer hormone pills have the same home problem. Hershman and colleagues followed 8,769 women in a Kaiser Permanente study. Of those who filled at least one prescription, 31% stopped early. Among those who kept going, 28% did not take the medicine as prescribed. Both patterns were linked with a higher chance of death (Breast Cancer Research and Treatment, 2011). A clean discharge note does not tell you if she is still taking the pill in month four.
What the hospital still owns
Leaders set the path between the unit, the clinic, and home. The surgeon, the oncology team, the navigator, and the family need one plan. Hot flashes, joint pain, and low mood often start after she leaves. If no one asks until the next visit, she may stop the pill and not say why.
Informal cancer caregivers are often left out of that plan. A spouse or adult child may be the person who hears, "My joints hurt. I am done." If they have no secure way to reach the team, the first signal is a missed refill or a worried phone call.
Ask three questions this month. Who owns the hormone-pill plan after discharge? Is a caregiver named, with her consent? Does a navigator see a missed dose before the phone rings?
A home signal the team can use
MyNavigator is a HIPAA-compliant platform that connects the clinical team, the patient, and informal caregivers. Education can match her reading level, with audio and video for people who learn better that way. Symptom check-ins can go out when side effects are most likely, by text or voice. The team gets an alert only when a set threshold is met, not for every small note.
Transition-of-care alerts can flag the move from hospital to home. Reports can show engagement, symptom trends, and adherence patterns for quality work with payers and accreditors. The platform is built to sit with the EHR you already use. It does not ask you to replace Epic, Cerner, or Flatiron. Time-stamped notes can also support Principal Illness Navigation billing, so the coordination work is not invisible.
Patients and caregivers use MyCure Team, the companion app, for a daily checklist, symptom and mood logging, and secure chat with the people she chooses. You can read how the clinical side works on the medical provider page.
One next step
If the discharge plan ends when the packet is signed, the pill years are still open. Schedule a demo to see a home plan the surgeon, the navigator, and the family can share. Start at the demo request form.
Sources
- Vyas et al., Journal of Managed Care and Specialty Pharmacy, 2022. Predictors of adherence to oral anticancer medications: an analysis of 2010-2018 U.S. nationwide claims.
- Hershman et al., Breast Cancer Research and Treatment, 2011. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Written by
Avident Health Team
Avident Health Team
Articles from the Avident Health team on cancer care navigation, treatment adherence, and support for patients and caregivers.



